Treatment duration as a surrogate endpoint to evaluate the efficacy of crizotinib in sequential therapy for patients with advanced ALK‐positive non‐small cell lung cancer: A retrospective, real‐world study

Treatment duration as a surrogate endpoint to evaluate the efficacy of crizotinib in sequential therapy for patients with advanced ALK‐positive non‐small cell lung cancer: A retrospective, real‐world study

Abstract Objectives Crizotinib has demonstrated good efficacy in patients with anaplastic lymphoma kinase (ALK)‐positive non‐small cell lung cancer (NSCLC). Continuing crizotinib therapy beyond progressive disease (CBPD) can achieve ongoing survival benefit in real‐world clinical practice. In terms...

Deskribapen osoa

Xehetasun bibliografikoak
Egile Nagusiak: Guangjian Yang, Di Ma, Haiyan Xu, Lu Yang, Junling Li, Puyuan Xing, Xuezhi Hao, Yan Wang
Formatua: Artikulua
Hizkuntza:English
Argitaratua: Wiley 2019-10-01
Saila:Cancer Medicine
Gaiak:
anaplastic lymphoma kinase inhibitor
crizotinib
crizotinib continuation beyond progressive disease
non‐small cell lung cancer
treatment duration
Sarrera elektronikoa:https://doi.org/10.1002/cam4.2420

Internet

https://doi.org/10.1002/cam4.2420

Antzeko izenburuak